Ainos to Begin Clinical Trial of HIV Treatment at Taiwan Hospital

Ainos Announces Clinical Trial for HIV Treatment

Ainos, Inc., a biopharmaceutical company, has revealed plans to commence a clinical trial for its HIV treatment, Veldona, at Taipei Medical University Hospital in Taiwan 1

1

. This development marks a significant step in the company's efforts to address the global HIV epidemic.

About Veldona

Veldona is Ainos' proprietary formulation of VELDONA®, a low-dose oral interferon-alpha (IFN-α) originally developed by Hayashibara Biochemical Laboratories, Inc. 2

2

. The treatment has shown promise in potentially treating HIV-1 infected patients, leading to this upcoming clinical study.

Clinical Trial Details

The clinical trial, set to begin in the third quarter of 2023, will be conducted at Taipei Medical University Hospital 1

1

. The study aims to evaluate the safety and efficacy of Veldona in HIV-1 infected patients who are currently on antiretroviral therapy (ART) 2

2

.

Study Objectives

The primary objective of the trial is to assess the impact of Veldona on HIV-1 viral load and CD4+ T cell count in patients 2

2

. These are crucial markers in determining the effectiveness of HIV treatments. Additionally, the study will examine Veldona's potential to reduce inflammation and immune activation in HIV-1 infected individuals.

Significance of the Trial

This clinical trial represents a crucial step in Ainos' mission to develop innovative treatments for HIV. If successful, Veldona could offer a new approach to managing HIV infections, potentially improving outcomes for patients worldwide 1

1

.

Company Background

Ainos, Inc. is a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic biology 2

2

. The company's approach combines multiple cutting-edge technologies to create potential breakthrough solutions for various health challenges.

Market Impact

The announcement of this clinical trial has generated interest in the biotech and pharmaceutical sectors. Investors and industry observers are closely watching Ainos' progress, as positive results from this study could significantly impact the company's market position and the broader field of HIV treatment 1

1

.